$heff's $tation of $tocks & $olid DD

[crudeoil24]

ONCE >> 5,500,000 shares @ $15 - 17 Managers: JPMorgan, Credit Suisse Spark's most advanced product candidate is currently in Phase 3 clinical trials with results expected in the second half of 2015. The product has received both breakthrough therapy designation and orphan product designation, meaning preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies and qualifies for certain development incentives. The fast-track status has gained the interest of the buyside and the deal is already well oversubscribed.